160 related articles for article (PubMed ID: 30796510)
1. CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.
Lin XR; Zhou XL; Feng Q; Pan XY; Song SL; Fang H; Lei J; Yang JL
J Cancer Res Clin Oncol; 2019 May; 145(5):1123-1132. PubMed ID: 30796510
[TBL] [Abstract][Full Text] [Related]
2. Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells.
Liu FR; Bai S; Feng Q; Pan XY; Song SL; Fang H; Cui J; Yang JL
BMC Cancer; 2018 Nov; 18(1):1087. PubMed ID: 30419845
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glioma by adenovirus KGHV500 encoding anti-p21Ras scFv and carried by cytokine-induced killer cells.
Qian J; Yang M; Feng Q; Pan XY; Yang LL; Yang JL
Exp Biol Med (Maywood); 2021 May; 246(10):1228-1238. PubMed ID: 33535808
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer.
Dai F; Zhang PB; Feng Q; Pan XY; Song SL; Cui J; Yang JL
J Cancer; 2021; 12(9):2768-2776. PubMed ID: 33854636
[No Abstract] [Full Text] [Related]
5. The antitumor efficacy of anti-p21Ras scFv mediated by the dual-promoter-regulated recombinant adenovirus KGHV300.
Pan XY; Liu XJ; Li J; Zhen SJ; Liu DX; Feng Q; Zhao WX; Luo Y; Zhang YL; Li HW; Yang JL
Gene Ther; 2017 Jan; 24(1):40-48. PubMed ID: 27834948
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Adenovirus KGHV500 and CIK Cells Codeliver Anti-p21-Ras scFv for the Treatment of Gastric Cancer with Wild-Type Ras Overexpression.
Wang M; Hong Y; Feng Q; Pan X; Song S; Cui J; Lei J; Fang H; Yang J
Mol Ther Oncolytics; 2018 Dec; 11():90-101. PubMed ID: 30534583
[TBL] [Abstract][Full Text] [Related]
7. The antitumor efficacy of a novel adenovirus-mediated anti-p21Ras single chain fragment variable antibody on human cancers in vitro and in vivo.
Yang JL; Pan XY; Zhao WX; Hu QC; Ding F; Feng Q; Li GY; Luo Y
Int J Oncol; 2016 Mar; 48(3):1218-28. PubMed ID: 26780944
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.
Yang Z; Zhang Q; Xu K; Shan J; Shen J; Liu L; Xu Y; Xia F; Bie P; Zhang X; Cui Y; Bian XW; Qian C
PLoS One; 2012; 7(9):e44802. PubMed ID: 23028626
[TBL] [Abstract][Full Text] [Related]
9. The immunoreactivity of the anti-p21Ras single-chain fragment variant KGH-R1 and its predicted binding sites to p21Ras.
Wang P; Pan X; Feng Q; Zou H; Cui J; He Y; Luo Y; Yang J
Immunotherapy; 2020 Aug; 12(12):879-890. PubMed ID: 32664770
[No Abstract] [Full Text] [Related]
10. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
11. BR2 cell penetrating peptide effectively delivers anti-p21Ras scFv to tumor cells with ganglioside expression for therapy of ras-driven tumor.
Yu T; Shi Y; Pan X; Feng Q; Wang P; Song S; Yang L; Yang J
PLoS One; 2022; 17(6):e0269084. PubMed ID: 35648774
[TBL] [Abstract][Full Text] [Related]
12. RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.
Huang CC; Liu FR; Feng Q; Pan XY; Song SL; Yang JL
BMC Cancer; 2021 Mar; 21(1):321. PubMed ID: 33765976
[TBL] [Abstract][Full Text] [Related]
13. A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues.
Yang JL; Liu DX; Zhen SJ; Zhou YG; Zhang DJ; Yang LY; Chen HB; Feng Q
BMC Cancer; 2016 Feb; 16():131. PubMed ID: 26897358
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide.
Du Y; Lin X; Feng Q; Pan X; Song S; Yang J
Anticancer Drugs; 2022 Jan; 33(1):e562-e572. PubMed ID: 34338241
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Tao L; Huang G; Shi S; Chen L
Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
[TBL] [Abstract][Full Text] [Related]
16. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma.
Wei C; Wang W; Pang W; Meng M; Jiang L; Xue S; Xie Y; Li R; Hou Z
Tumour Biol; 2014 Mar; 35(3):1997-2007. PubMed ID: 24104501
[TBL] [Abstract][Full Text] [Related]
17. RGD-p21Ras-scFv expressed prokaryotically on a pilot scale inhibits ras-driven colorectal cancer growth by blocking p21Ras-GTP.
Lin P; Qian J; Huang CC; Xu WM; Wang YY; Gao ZR; Zheng SQ; Wang P; Jia DQ; Feng Q; Yang JL
BMC Cancer; 2024 Jan; 24(1):71. PubMed ID: 38216883
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
19. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).
Yoon SH; Lee JM; Woo SJ; Park MJ; Park JS; Kim HS; Park MY; Sohn HJ; Kim TG
J Clin Immunol; 2009 Nov; 29(6):806-14. PubMed ID: 19517218
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
